Stuart Therapeutics, a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced the addition of Lukas Scheibler, PhD as its Chief Science and Technology Officer.